Palmoplantar psoriasis and palmoplantar pustulosis are chronic skin diseases with a large impact on patient quality of life. They are frequently refractory to treatment, being generally described as a therapeutic challenge. This article aims to review the definitions of palmoplantar psoriasis and palmoplantar pustulosis, highlighting the similarities and differences in terms of epidemiology, clinical presentation, genetics, histopathology, and pathogenesis, as well as treatment options for both entities. Classical management of mild to moderate palmoplantar pustulosis and palmoplantar psoriasis relies on use of potent topical corticosteroids, phototherapy, and/or acitretin. Nevertheless, these drugs have proven to be insufficient in long-term control of extensive disease. Biologic therapy-namely, anti-interleukin-17 agents and phosphodiesterase type 4 inhibitors-has recently shown promising results in the treatment of palmoplantar psoriasis. Knowledge of the pathophysiologic pathways of both entities is of utmost importance and may, in the future, allow development of molecularly targeted therapeutics.
SummaryBackground. The increasing use of long-lasting nail aesthetic products has led to a growing number of cases of allergic contact dermatitis (ACD) caused by (meth)acrylates in recent years. Objectives. To provide information on ACD caused by (meth)acrylates related to nail cosmetic products. Methods. We retrospectively reviewed files of patients with ACD caused by (meth)acrylates related to nail cosmetic products, who were patch tested between January 2011 and December 2015 in 13 departments of dermatology in Portugal. Results. Two-hundred and thirty cases of ACD caused by (meth)acrylates (55 technicians, 56 consumers, and 119 with mixed exposure) had been documented, mostly as chronic hand eczema (93%). The most common sensitizers were: 2-hydroxyethyl methacrylate (HEMA), which was positive in 90% of the tested patients, 2-hydroxypropyl methacrylate (HPMA), which was positive in 64.1%, and ethyleneglycol dimethacrylate, which was positive in 54.5%. Conclusion. HEMA and HPMA were the most frequent positive allergens. HEMA, which identified 90% of cases, can be considered to be a good screening allergen. The high number of cases of ACD caused by (meth)acrylates in nail cosmetic products certainly warrants better preventive measures at the occupational level, and specific regulation in the field of consumer safety.
Introduction: There is a paucity of information regarding chronic urticaria patients’ care in a real-world setting. The objective of this study was to report and evaluate the baseline characteristics of Portuguese chronic urticaria patients refractory to H1-antihistamines included in the AWARE study. Material and Methods: This is a non-interventional cohort study. Adult patients with a diagnosis of chronic urticaria with symptoms for at least two months, refractory to H1-antihistamines, consulting one of the 10 participating urticaria centers throughout Portugal have been included in the study. Baseline sociodemographic data, medical history, clinical parameters, medication, weekly urticaria activity score, and dermatology quality of life index have been collected. Results: Seventy six patients were included, of which 76.3% were women. The majority of patients had a diagnosis of chronic spontaneous urticaria (88.2%) and 39.5% had angioedema. Around 91.0% of patients were medicated with non-sedative H1-antihistamines and 35.4% with a third line therapy. Median dermatology quality of life index was 5.0 and median weekly urticaria activity score was 13.0. Discussion: The baseline results suggest that patients with chronic urticaria refractory to H1-antihistamines are being under-treated in the real-world setting. Conclusion: The AWARE study demonstrates the real impact of chronic urticaria on Portuguese patients refractory to H1-antihistamines treatment, and 30% report a very large or extremely large deleterious effect on their quality of life. The follow-up of these patients will allow evaluating strategies aimed at optimizing disease control.
RESUMO Introdução: O ustekinumab é um anticorpo monoclonal dirigido contra a subunidade p40 presente nas IL-12 e 23. A evidência da sua eficácia e segurança em ensaios clínicos é amplamente conhecida. No entanto a evidência da sua utilização na prática clínica é relativamente limitada na população Portuguesa. O objetivo deste trabalho é relatar a experiência de dois serviços de dermatologia Portugueses no tratamento da psoríase moderada a grave com ustekinumab. Material e Métodos: Foram avaliados os dados clínicos, demográficos, e de resposta terapêutica ao ustekinumab em 116 doentes com psoríase tratados entre novembro de 2009 e dezembro de 2015. Resultados: Observou-se uma resposta terapêutica ≥ PASI75 em 67,2%, 85,3%, 89,6% e 88,7% dos doentes às semanas 4, 12, 24 e 52, respetivamente. O ustekinumab foi descontinuado em sete doentes (três por falências primárias, três por falências secundárias e um por evento adverso). Não foram observados eventos cardiovasculares nem reativações de infecções prévias (tuberculose, hepatite B). Em nove doentes foi utilizado em simultâneo metotrexato, e em catorze foi necessário otimizar a dose de ustekinumab. Não foram observados efeitos colaterais nestes grupos. A resposta terapêutica foi superior nos doentes naïve a terapêuticas biológicas comparativamente com os doentes não-naïve. Observou-se uma tendência para resposta clínica inferior nos doentes com peso entre 90 -100 kg. Discussão e Conclusão: Este estudo confirma a segurança e eficácia de ustekinumab no tratamento da psoríase moderada a grave em doentes da prática clínica real, sustenta a eficácia mesmo nos doentes previamente expostos a terapêutica biológica e aponta para a possível necessidade de ajustar a dose a partir dos 90 kg. Palavras-chave: Biológicos/uso terapêutico; Psoríase/tratamento; Ustekinumab/uso terapêutico ABSTRACT Introduction:Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines.Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in clinical practice is limited. Our objective is to report on the real-life experience of two Portuguese dermatology departments with ustekinumab in patients with moderate to severe psoriasis, and to identify the clinical characteristics associated with a weaker clinical response. Material and Methods: Clinical, demographic, and therapeutic response data was retrospectively collected in 116 patients with moderate to severe psoriasis treated with ustekinumab between November 2009 and December 2015.Results: A PASI75 therapeutic response was observed in 67.2%, 85.3%, 89.6% and 88.7% of patients at weeks 4, 12, 24 and 52, respectively. Ustekinumab was discontinued in seven patients (three due to primary failure, three due to secondary treatment failure, and one due to adverse events). Neither cardiovascular events nor cases of reactivation of previous infections (tuberculosis, hepatitis B) were observed during follow-up. In nine patients methotrexate was u...
Psoriasis is a chronic, immune-mediated inflammatory disorder associated with systemic inflammation and a significantly increased risk of cardiovascular disease. Common pathologic mechanisms are likely involved in the pathogenesis of psoriasis and atherosclerosis, including similar inflammatory cytokine profiles and proinflammatory cell types. The hypothesis that aggressive treatment of skin inflammation may decrease the risk of developing atherosclerosis and consequently cardiovascular disease is currently a focus of major attention. Interleukin (IL)-17 may be an important cytokine linking skin disease to vascular disease/inflammation. However, the role of IL-17 in atherosclerosis is still controversial, as IL-17 may exhibit pro-atherogenic or anti-atherogenic effects depending on the specific tissue, cellular, and immune context. Given the development of several IL-17 inhibitors, the investigation of IL-17 inhibition impact on cardiovascular outcome is extremely important.
The radiologist must be familiar with the morphologic and functional MRI appearances of surgical complications in patients with palliated or repaired cyanotic congenital heart disease to deliver an accurate diagnosis on which to base management decisions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.